COPD drugsgo head to head

Thursday, January 31, 2008

LONDON - Clinical trial results show Glaxo's Advair has an edge over Pfizer's Spiriva in treating patients with COPD, Reuters reported Dec. 28. A two-year study of 1,300 patients found both drugs had a similar impact on rate of exacerbations, but patients treated with Advair gained a significant improvement in health status and greater survival benefit than those on Spiriva, according to Glaxo. Results of the first head-to-head study of the two drugs were published in the American Journal of Respiratory and Critical Care Medicine.